MARKET

EYPT

EYPT

Eyepoint Pharmac
NASDAQ
5.71
+0.33
+6.13%
After Hours: 5.60 -0.11 -1.93% 18:54 04/14 EDT
OPEN
5.51
PREV CLOSE
5.38
HIGH
5.76
LOW
5.14
VOLUME
925.48K
TURNOVER
--
52 WEEK HIGH
22.30
52 WEEK LOW
3.910
MARKET CAP
392.44M
P/E (TTM)
-2.4563
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EYPT last week (0407-0411)?
Weekly Report · 12h ago
Weekly Report: what happened at EYPT last week (0331-0404)?
Weekly Report · 04/07 10:50
Weekly Report: what happened at EYPT last week (0324-0328)?
Weekly Report · 03/31 11:00
Weekly Report: what happened at EYPT last week (0317-0321)?
Weekly Report · 03/24 10:50
Weekly Report: what happened at EYPT last week (0310-0314)?
Weekly Report · 03/17 10:59
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 03/14 12:12
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)
TipRanks · 03/10 23:50
Weekly Report: what happened at EYPT last week (0303-0307)?
Weekly Report · 03/10 11:00
More
About EYPT
More
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Recently
Symbol
Price
%Change

Webull offers Eyepoint Pharmaceuticals Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.